Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Dec;68(6):1110–1114. doi: 10.1038/bjc.1993.489

The effects of pentoxifylline on the relative perfusion of tumours growing in three sites in the mouse.

P L Sensky 1, V E Prise 1, A E Ward 1, D G Hirst 1
PMCID: PMC1968634  PMID: 8260361

Abstract

The haemorheological agent pentoxifylline (PTX) has been shown to improve the relative perfusion and oxygenation of subcutaneous tumours in the mouse. In order to establish whether this effect is dependent on the site of tumour growth, we have looked at changes in the distribution of the cardiac output (COD) to the murine NT carcinoma grown either intradermally (i.d.), intramuscularly (i.m.), on the wall of the caecum, or in all three sites, following i.p. administration of 50 mg kg-1 PTX. In animals bearing a single tumour, PTX treatment significantly increases the COD to tumours located in the caecum, but has no significant effect on the COD to those located in the i.d. or i.m. sites. If all three tumours are present in a single animal, the COD to all three tumours is significantly enhanced by PTX. This appears to reflect the presence of the caecum tumour and does not appear to relate to changes in tumour size or to the haematocrit (HCT) of the blood. We propose that this site dependency implies that a significant increase in blood viscosity only occurs in animals with tumours located in specific sites. Therefore, the potential radiosensitising capability of PTX is highly dependent on tumour location.

Full text

PDF
1110

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrus J. L., Ambrus C. M., Gastpar H. Studies on platelet aggregation with pentoxifylline: effect on neoplastic disorders and other new indications. J Med. 1979;10(5):339–345. [PubMed] [Google Scholar]
  2. Aviado D. M., Porter J. M. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984 Nov-Dec;4(6):297–307. doi: 10.1002/j.1875-9114.1984.tb03380.x. [DOI] [PubMed] [Google Scholar]
  3. Dion M. W., Hussey D. H., Osborne J. W. The effect of pentoxifylline on early and late radiation injury following fractionated irradiation in C3H mice. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):101–107. doi: 10.1016/0360-3016(89)90376-3. [DOI] [PubMed] [Google Scholar]
  4. Dormandy J., Ernst E., Flute P. Increase in red cell filterability after incubation with oxpentifylline. Curr Med Res Opin. 1981;7(8):520–522. doi: 10.1185/03007998109112367. [DOI] [PubMed] [Google Scholar]
  5. Gastpar H., Ambrus J. L., Ambrus C. M. Studies on platelet aggregation in vivo. VII: Effect of pentoxyfylline on circulating tumor cells. J Med. 1978;9(3):265–268. [PubMed] [Google Scholar]
  6. Hirst D. G., Hirst V. K., Shaffi K. M., Prise V. E., Joiner B. The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):211–218. doi: 10.1080/09553009114551861. [DOI] [PubMed] [Google Scholar]
  7. Hirst D. G., Joiner B., Hirst V. K. Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites. Br J Cancer. 1993 Jan;67(1):1–6. doi: 10.1038/bjc.1993.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jain R. K. Determinants of tumor blood flow: a review. Cancer Res. 1988 May 15;48(10):2641–2658. [PubMed] [Google Scholar]
  9. Jarret P. E., Moreland M., Browse N. L. The effect of oxpentifylline ('Trental') on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opin. 1977;4(7):492–495. doi: 10.1185/03007997709109338. [DOI] [PubMed] [Google Scholar]
  10. Lee I., Kim J. H., Levitt S. H., Song C. W. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys. 1992;22(3):425–429. doi: 10.1016/0360-3016(92)90846-a. [DOI] [PubMed] [Google Scholar]
  11. Matzky R., Darius H., Schrör K. The release of prostacyclin (PGI2) by pentoxifylline from human vascular tissue. Arzneimittelforschung. 1982;32(10):1315–1318. [PubMed] [Google Scholar]
  12. Mollitt D. L., Poulos N. D. The role of pentoxifylline in endotoxin-induced alterations of red cell deformability and whole blood viscosity in the neonate. J Pediatr Surg. 1991 May;26(5):572–574. doi: 10.1016/0022-3468(91)90709-3. [DOI] [PubMed] [Google Scholar]
  13. Müller R. Pentoxifylline -- a biomedical profile. J Med. 1979;10(5):307–329. [PubMed] [Google Scholar]
  14. SAPIRSTEIN L. A. Regional blood flow by fractional distribution of indicators. Am J Physiol. 1958 Apr;193(1):161–168. doi: 10.1152/ajplegacy.1958.193.1.161. [DOI] [PubMed] [Google Scholar]
  15. Song C. W., Hasegawa T., Kwon H. C., Lyons J. C., Levitt S. H. Increase in tumor oxygenation and radiosensitivity caused by pentoxifylline. Radiat Res. 1992 May;130(2):205–210. [PubMed] [Google Scholar]
  16. Sowemimo-Coker S. O., Turner P. The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells. Eur J Clin Pharmacol. 1985;29(1):55–59. doi: 10.1007/BF00547369. [DOI] [PubMed] [Google Scholar]
  17. Ward A., Clissold S. P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50–97. doi: 10.2165/00003495-198734010-00003. [DOI] [PubMed] [Google Scholar]
  18. Weithmann K. U. Reduced platelet aggregation by pentoxifylline stimulated prostacyclin release. Vasa. 1981;10(3):249–252. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES